No services found
No Products found
10 ug, 100 ug, 50ug, 100ug
ProteoGenix
Recombinant Proteins
Mammalian cells
Elisa, WB
Human CD72 (Lys221-Asp359) recombinant protein is a protein that plays an important role in the immune system. It is a member of the CD5 family of transmembrane receptors and is primarily expressed on B cells. This protein has been extensively studied due to its potential as a drug target for various diseases. In this article, we will discuss the structure, activity, and potential applications of Human CD72 (Lys221-Asp359) recombinant protein.
The Human CD72 (Lys221-Asp359) recombinant protein is a glycoprotein with a molecular weight of approximately 40 kDa. It is composed of 338 amino acids and contains three extracellular immunoglobulin-like domains, a transmembrane domain, and a cytoplasmic tail. The extracellular domains are responsible for binding to ligands, while the cytoplasmic tail is involved in signal transduction.
Human CD72 (Lys221-Asp359) recombinant protein is primarily expressed on B cells and plays a crucial role in regulating B cell activation and differentiation. It acts as a co-receptor for the B cell receptor (BCR) and enhances BCR signaling, leading to increased B cell activation and proliferation. This protein also interacts with various ligands, including CD5, CD100, and CD84, and modulates B cell responses. Additionally, Human CD72 (Lys221-Asp359) recombinant protein has been shown to play a role in the development of autoimmune diseases and cancer.
Due to its involvement in various immune processes, Human CD72 (Lys221-Asp359) recombinant protein has been identified as a potential drug target for several diseases. Some of the potential applications of this protein are discussed below.
Autoimmune diseases are characterized by an abnormal immune response, where the body’s immune system attacks its own tissues. Human CD72 (Lys221-Asp359) recombinant protein has been shown to play a role in the development of autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Inhibition of this protein has been proposed as a therapeutic strategy for these diseases.
Human CD72 (Lys221-Asp359) recombinant protein has also been implicated in the development and progression of cancer. Studies have shown that this protein is overexpressed in various types of cancer, including B cell lymphoma, chronic lymphocytic leukemia, and multiple myeloma. Inhibition of Human CD72 (Lys221-Asp359) recombinant protein has been proposed as a potential treatment for these cancers.
Inflammatory diseases, such as asthma and inflammatory bowel disease, are characterized by chronic inflammation. Human CD72 (Lys221-Asp359) recombinant protein has been shown to play a role in regulating inflammatory responses. Inhibition of this protein has been suggested as a potential treatment for these diseases.
Human CD72 (Lys221-Asp359) recombinant protein has also been implicated in the immune response against infectious diseases. Studies have shown that this protein is involved in the regulation of B cell responses to viral and bacterial infections. Inhibition of Human CD72 (Lys221-Asp359) recombinant protein has been proposed as a potential treatment for infectious diseases.
Reviews
There are no reviews yet.
Your email address will not be published. Required fields are marked *
Your review *
Name *
Email *
Save my name, email, and website in this browser for the next time I comment.
Send us a message from the form below
First name
Last name
Email address
Lab / Company
Phone number
Message
send
Your cart is currently empty.